Prescribing for Older Adults: Managing Dementia in Aging
This paper examines dementia as a psychiatric disorder disproportionately affecting older adults, with a focus on the role of Psychiatric-Mental Health Nurse Practitioners (PMHNPs) in its management. It reviews the clinical features and types of dementia — including Alzheimer's disease, vascular dementia, and frontal-temporal dementia — and evaluates three treatment approaches: FDA-approved pharmacotherapy (aducanumab), off-label drug use (donepezil and cholinesterase inhibitors), and non-pharmacological interventions such as Cognitive Stimulation Therapy. The paper also assesses the risks and benefits of each approach and outlines relevant clinical practice guidelines for dementia care.
- Introduction: Mental Health and Aging: Psychiatric disorders are more common in older adults
- Understanding Dementia and Its Types: Dementia types, symptoms, and diagnostic overview
- FDA-Approved Treatment: Aducanumab: FDA-approved aducanumab reduces amyloid brain deposits
- Off-Label Drug Use: Cholinesterase Inhibitors: Donepezil used off-label to slow dementia symptoms
- Non-Pharmacological Interventions: Cognitive Stimulation Therapy addresses behavioral symptoms
- Risks, Benefits, and Clinical Practice Guidelines: Risk-benefit analysis and clinical recommendations for dementia
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Clearly organizes three distinct treatment categories — FDA-approved, off-label, and non-pharmacological — allowing direct comparison of approaches for the same condition.
- Grounds clinical recommendations in a specific professional role (PMHNP), giving the analysis a practical, applied perspective rather than a purely academic one.
- Balances pharmacological detail with patient-centered considerations such as caregiver involvement, side-effect counseling, and dignity in care.
Key academic technique demonstrated
The paper uses a comparative framework to evaluate multiple treatment modalities for a single disorder, citing FDA guidance, peer-reviewed journal articles, and clinical databases. This technique — systematically weighing benefits and risks across treatment options — is characteristic of evidence-based clinical writing in nursing and healthcare education.
Structure breakdown
The paper opens with a brief introduction on psychiatric disorders in aging, then defines dementia and its major subtypes. It proceeds through three treatment approaches in sequence, dedicating a short section to each. A combined risks-and-benefits section evaluates both pharmacological options, and a closing clinical guidelines section synthesizes best-practice recommendations for PMHNPs. The structure mirrors a clinical decision-making pathway.
Introduction: Mental Health and Aging
Some psychiatric disorders are more prevalent in older adults than in younger populations, largely due to cerebral-neural degeneration. These disorders are often not recognized in time and are therefore not treated properly, despite their prevalence. Mental disorders in older adults can lead to disability, suicide, or a significantly diminished quality of life. This paper examines one such disorder from the DSM-5 that disproportionately affects older adults: dementia.
Understanding Dementia and Its Types
Dementia is a disorder characterized by the inability to make sound decisions, think clearly, or recall information that was once easy to remember. Many people mistakenly assume that dementia is a normal part of aging, but this is not the case. Early signs include forgetting to eat a meal or how to prepare one, becoming disoriented, and losing familiarity with once-familiar routes. People with dementia may also experience impaired judgment — for example, a farmer may lose the insight to know what to plant in a given season. Dementia has also been associated with hallucinations and loss of balance.
There are many types of dementia, but the most common — accounting for approximately 80% of cases — is Alzheimer's disease. This disease has no cure, though medications that help protect the brain can be administered. Other forms of dementia include mixed dementia, vascular dementia, and frontal-temporal dementia. Dementia can be diagnosed by a healthcare practitioner, who may then prescribe various methods of treatment and strategies to manage the disorder. As a Psychiatric-Mental Health Nurse Practitioner (PMHNP), the recommended course of treatment typically encompasses FDA-approved drugs, off-label (non-FDA-approved) drugs, and non-pharmacological interventions, depending on the stage and presentation of the condition.
FDA-Approved Treatment: Aducanumab
According to the Food and Drug Administration (2021), a new drug — aducanumab — was approved for use in dementia care. The drug does not treat Alzheimer's dementia directly, but it reduces the deposits of amyloid in the brain. This treatment helps affected older adults maintain greater dignity and can help control some cognitive symptoms. Aducanumab was approved through the FDA's accelerated approval program, which is designed to help people with dementia access treatment more quickly. Research from the FDA (2021) indicates that "the drug is believed to provide meaningful therapeutic benefit over existing treatments." As Mahase (2021) notes, however, the FDA did not specify eligibility criteria for the drug in particular patient populations at the time of approval.
Create your account
Always verify citation format against your institution’s current style guide requirements.